News

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The...

Tryton Medical First U.S. Patient Extended Access Registry

Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. 

September 9, 2014 — Tryton Medical Inc. announced an initial closing of an aggregate $20 million private equity financing. Participating in this financing were existing investors RiverVest Venture...

Cook Medical Zilver PTX Drug Eluting Peripheral Stent Clinical Study China

Cook Medical has enrolled the first patient in the clinical study in China of its Zilver PTX Drug Eluting Peripheral Stent. The case was performed by one of the study’s principal investigators,...

MicroVention LVIS Stent FDA Clearance July 2014

The U.S, Food and Drug Administration (FDA) has cleared MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.), which is a stent and delivery system...

bioresorbable stents, dissolving stents, Absorb stent, BVS

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents...

September 3, 2014 — Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. The Cook Medical VIVO clinical research study aims to determine...

August 28, 2014 — Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new...

Patient Enrollment REDUCE Sudy Combo Dual Therapy Stent OrbusNeich

OrbusNeich announced first patient enrollment in the Randomized Evaluation of short-term Dual anti platelet therapy in patients with acute coronary syndrome treated with the Combo Dual Therapy...

Biotronik Enrollment Completion SFA Arm BIOFLEX-I Study Pulsar-18 4-French

Biotronik announced the completion of patient enrollment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an U.S. Food and Drug Administration (FDA)-approved...

Tryton Side Branch Stent EXTENDED Access Registry

Tryton Medical Inc. announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm clinical study of its Tryton Side Branch Stent....

July 30, 2014 — OrbusNeich announced the first patient has been enrolled in the Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry. The first Combo dual...

July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the company's latest-generation bare...

stentys, stent, self-apposing stent

Stentys has announced the publication of an article in the Journal of the American College of Cardiology (JACC) entitled, "Causes of Early Stent Thrombosis in Patients Presenting with Acute...

July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical...

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to continue the development of a bioresorbable, self-...

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable...

OrbusNeich Patient Enrollment Completion REMEDEE Registry Combo Stent

OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal...